Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
W. Zhang
Observed name:
Wei Zhang
Institution:
Fudan University Shanghai Cancer Center
Observed institutions:
University of Southern California,
Oregon Health & Science University,
Chinese Academy of Medical Sciences & Peking Union Medical College,
Fudan University Shanghai Cancer Center,
USC Norris Comprehensive Cancer Center,
Cancer Hospital of Chinese Academy of Medical Sciences
show all 6
ORCID:
0000-0003-0282-601X
Observed ORCID:
0000-0003-0282-601X
OpenAlex ID:
A5013703955
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
2011
·
S. Iqbal
, B. Goldman
, et al.
·
Annals of Oncology
·
164
PDF
Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab
2006
·
W. Zhang
, M. Gordon
, et al.
·
Journal of Clinical Oncology
·
21
Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
2009
·
A. B. El-Khoueiry
, A. Pohl
, et al.
·
Journal of Clinical Oncology
·
13
Molecular determinants of cetuximab efficacy
2005
·
D. Vallböhmer
, W. Zhang
, et al.
·
Journal of Clinical Oncology
·
10
Association of Cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225)
2004
·
W. Zhang
, J. Yun
, et al.
·
Journal of Clinical Oncology
·
10
VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer
2009
·
Y. Ning
, G. Lurje
, et al.
·
Journal of Clinical Oncology
·
8
VEGF and VEGF receptor-2 (VEGFR2) gene polymorphisms predict tumor recurrence in stage II and III colon cancer
2007
·
G. Lurje
, A. M. Schultheis
, et al.
·
Journal of Clinical Oncology
·
7
Survival differences related to estrogen receptor beta (ERβ) polymorphism and age in female patients with metastatic colon cancer
2004
·
O. A. Press
, W. Zhang
, et al.
·
Journal of Clinical Oncology
·
7
Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin
2006
·
F. Nagashima
, W. Zhang
, et al.
·
Journal of Clinical Oncology
·
6
Use of genetic variants to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
2009
·
H. Singh
, A. Pohl
, et al.
·
Journal of Clinical Oncology
·
5
Molecular prognostic factors of irinotecan efficacy
2005
·
D. Y. Yang
, D. Vallböhmer
, et al.
·
Journal of Clinical Oncology
·
5
Genomic profile associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab
2005
·
W. Zhang
, D. Vallböhmer
, et al.
·
Journal of Clinical Oncology
·
4
HIF-responsive lncRNAs define an immunosuppressive phenotype and predict anti-angiogenic response in clear cell renal cell carcinoma
2026
·
Yongqiang Huang
, Wei Zhang
, et al.
·
Journal of the Renin-Angiotensin-Aldosterone System
·
3
1952P Comprehensive profiling of MDM2 amplified gastrointestinal (GI) cancers
2020
·
F. Battaglin
, J. Xiu
, et al.
·
Annals of Oncology
·
2
473P PLK1 expression and KRAS mutations in colorectal cancer
2020
·
P. Jayachandran
, A. Elliott
, et al.
·
Annals of Oncology
·
2
Use of sex-specific genomic profile to predict clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5- fluorouracil/oxaliplatin
2007
·
M. A. Gordon
, W. Zhang
, et al.
·
Journal of Clinical Oncology
·
2
Gene expression levels of HER2 and IL-8 and polymorphism in IL-8 associated with clinical outcome in advanced or metastatic gastric cancer treated with lapatinib in SWOG 0413 trial
2007
·
H. Chang
, M. Azuma
, et al.
·
Journal of Clinical Oncology
·
2
Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy
2004
·
D. J. Park
, J. Yun
, et al.
·
Journal of Clinical Oncology
·
2
Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin
2004
·
J. Yun
, W. Zhang
, et al.
·
Journal of Clinical Oncology
·
2
55P DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
2023
·
W. Zhang
, Y. Wang
, et al.
·
Immuno-Oncology Technology
·
1
PDF
480P Gene expression of NANOG and NANOGP8 in colorectal cancer
2021
·
H. Arai
, Y. Baca
, et al.
·
Annals of Oncology
·
1
Large-scale analysis of CDH1 mutations define a distinctive molecular subset in gastric cancer (GC)
2019
·
J. Wang
, J. Xiu
, et al.
·
Annals of Oncology
·
1
Colorectal cancer susceptibility variants and clinical outcome in adjuvant and metastatic colorectal cancer
2009
·
H. Lenz
, G. Lurje
, et al.
·
Journal of Clinical Oncology
·
1
Polymorphisms in estrogen receptor beta, interleukin-8, and interleukin-8 receptor associated with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil/oxaliplatin
2007
·
R. D. Ladner
, M. A. Gordon
, et al.
·
Journal of Clinical Oncology
·
1
Molecular predictor of irinotecan (CPT-11) efficacy
2005
·
K. E. Rhodes
, D. Vallböhmer
, et al.
·
Journal of Clinical Oncology
·
1
Show more works
View as search
Works count:
40
Citation count:
281
H-index:
7
I10-index:
5
Year
Topic
Type